Biofrontera Inc. (BFRI)
(Delayed Data from NSDQ)
$1.54 USD
-0.06 (-3.75%)
Updated May 8, 2024 03:59 PM ET
After-Market: $1.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
BFRI 1.54 -0.06(-3.75%)
Will BFRI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BFRI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BFRI
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
BFRI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should Know
All You Need to Know About Biofrontera Inc. (BFRI) Rating Upgrade to Buy
Biofrontera Inc. (BFRI) Reports Q2 Loss, Lags Revenue Estimates
Other News for BFRI
Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024
Biofrontera files to sell 11.31M shares for holders
Biofrontera Milestones Extend Warrants and Boost Investor Confidence
Biofrontera Inc. achieves two milestones associated with Series B-3 warrants
Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants